ライブ
FierceBiotechSanofi CFO defends Hudson’s Dupixent legacy, but accepts ‘number of setbacks’ in R&DFierceBiotechFrom debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spreeThermo FisherThermo Fisher Scientific (NYSE:TMO) Beats Q1 Estimates But Stock Drops in Pre-Market - ChartMill10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - Yahoo Finance SingaporeThermo FisherThermo Fisher posts quarterly results beat as lab products, biopharma services grow - ReutersThermo FisherTHERMO FISHER SCIENTIFIC ($TMO) Releases Q1 2026 Earnings - Quiver QuantitativeAgilentUniversal Beteiligungs und Servicegesellschaft mbH Sells 54,276 Shares of Agilent Technologies, Inc. $A - MarketBeatThermo Fisher[8-K] THERMO FISHER SCIENTIFIC INC. Reports Material Event - Stock TitanThermo FisherThermo Fisher Scientific Reports First Quarter 2026 Results - Yahoo FinanceAgilentBoston Trust Walden Corp Sells 21,880 Shares of Agilent Technologies, Inc. $A - MarketBeatThermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Borrow Rate - Xã Thanh HàAgilentIs Agilent Technologies a Better Buy Than Danaher? - Trefis
FierceBiotech 2026年1月6日

Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact

Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact

原文
本文は利用できません。元の情報源をご確認ください。